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Abstract
Saxagliptin is a potent, selective DPP4 inhibitor. Highlights from abstracts presented at the 2010 meetings of the
European Association for the Study of Diabetes and the American Diabetes Association include studies and
analyses that shed light on the promising role for saxagliptin within the management of type 2 diabetes mellitus.
Data show that saxagliptin combination therapy improves HbA1c levels compared with placebo, particularly in
patients with high HbA1c at baseline, long duration of disease, low baseline creatinine clearance, and low
homeostasis model assessment 2 b-cell function at baseline. These efficacy benefits are achieved without any
increase in hypoglycemia or other adverse events. The study results also show that the saxagliptin plus metformin
combination is a good candidate for initial therapy in drug-naïve patients treated for as long as 72 weeks. Survey
data presented confirm that hypoglycemia (and fear of hypoglycemia) is a barrier to patients’ acceptance of
diabetes treatment, limiting its efficacy. Therefore, therapies such as saxagliptin that have a low risk of
hypoglycemia may be more acceptable to patients in helping them to achieve glycemic control and to optimize
their quality of life. In patients with renal impairment, for whom metformin is contraindicated, saxagliptin
monotherapy is a promising option for antidiabetic management as, when given at a reduced dose, it is
well-tolerated with a safety profile similar to that of placebo.
Introduction
The dipeptidyl peptidase-4 (DPP4) inhibitors are a novel
class of antidiabetic drugs with a good safety profile and
which are now being considered in some algorithms for
the treatment of type 2 diabetes mellitus (T2DM).
As evidence accumulates, it is likely that they will
occupy a more predominant role. We present here some
of the key data on saxagliptin (SAXA) - a potent, selec-
tive DPP4 inhibitor - derived from abstracts presented
at the 2010 meetings of the American Diabetes
Association (ADA) and the European Association for
the Study of Diabetes (EASD).
Efficacy of saxagliptin as an add-on therapy
At EASD, Allen et al presented a pooled analysis of Phase
III trials comparing SAXA with placebo as an add-on
therapy to metformin (MET), sulphonylureas (SU) or
thiazolidinedione (TZD) [1]. Patients with T2DM
recruited into the studies were aged >18 years, with
HbA1c ≥7%. The aim of the analysis was to evaluate any
potentially important relationships between patient char-
acteristics at baseline and the efficacy of SAXA 5 mg/day
over a 24-week period. The following subgroups were
defined according to baseline characteristics: gender
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(< 65, ≥65 years); T2DM duration (≤1.5, ≤3, >3- < 5, ≥5,
≥10 years); creatinine clearance (≤0.8, >0.8 mL/s); home-
ostasis model assessment 2 b-cell function (HOMA-2B;
≤ and >58.6; baseline study median). The efficacy of
SAXA (mean change from baseline in HbA1c versus pla-
cebo at week 24) was determined for each subgroup cate-
gory. The results demonstrate that HbA1c lowering from
baseline was greater with SAXA than with placebo. The
decreases in HbA1c ranged from -0.52% to -0.93% across
the diverse demographic and T2DM subgroups, includ-
ing gender, BMI, age, and renal function. There was a
trend toward larger mean HbA1c decreases in patients
with longer duration of T2DM (≥5 years), lower baseline
creatinine clearance, and lower baseline HOMA-2B [1].
The same group also analyzed the relationship between
the efficacy of SAXA and baseline HbA1c in the Phase III
trial pooled results [2]. As expected from previous metar-
egression analyses of trials with various oral antidiabetic
drugs, the reductions in HbA1c were greater in patient
subgroups with higher HbA1c levels at baseline. In those
who had HbA1c 8.6-8.9% and ≥9%, the mean placebo-
corrected HbA1c reductions were -1% and -0.86%,
respectively. Among patients who were close to target
HbA1c at baseline (i.e. <7.5%), more than 50% achieved
target HbA1c < 7% without associated hypoglycemic epi-
sodes [2]. Other adverse events were not reported within
the abstract.
Saxagliptin has similar efficacy without increasing
hypoglycemia when compared with other insulin
secretagogues
The ability of SAXA to lower HbA1c without increasing
hypoglycemic episodes is due to its glucose-dependent
effect and it is one of the main advantages of incretins
when compared with other insulin secretagogues such
as SU. Göke et al at tested this hypothesis in a 52-week
multicenter, randomized, double-blind, noninferiority,
Phase IIIb trial comparing the efficacy and safety of add-
ing SAXA 5 mg/d or glipizide (GPZ) to MET in T2DM
patients inadequately controlled on MET with an HbA1c
> 6.5%-10% and on a stable MET dose ≥1500 mg/day.
GPZ was uptitrated as needed from 5 to 20 mg/day
(mean dose 14.7 mg/day; 51% received 20 mg/day) [3].
The results, which were presented at ADA, show that
the efficacy of SAXA is noninferior to GPZ when added
to MET, but treatment with SAXA was associated with
significantly fewer hypoglycemic events (3.0% vs 36.3%;
p < 0.0001) and a divergent favourable impact on body
weight (mean change -1.1 vs + 1.1 kg; p < 0.0001).
Treatment-related adverse events were less common
with SAXA compared with GPZ (9.8% vs 31.2%).
Excluding hypoglycemia, the proportion of patients
experiencing adverse events was similar in the two
groups (56.8% SAXA vs 54.9% GPZ) and discontinua-
tion rates due to adverse events were also similar
between groups (4%) [3].
Saxagliptin plus metformin as initial therapy in
drug-naïve patients
Perhaps one of the most interesting uses for the combi-
nation of a DPP4 inhibitor with MET may be as initial
therapy for T2DM, due to the fact that the former
would not add any titration problems nor adverse effects
when combined with MET. At ADA Pfützner et al pre-
sented the long-term results of a multicenter, rando-
mized, double-blind, active-controlled study, which had
a 24-week short-term period (primary) followed by a
52-week long-term extension (total 76 weeks) to assess
long-term efficacy and tolerability of initial combination
therapy with SAXA plus MET versus SAXA or MET
alone in drug-naïve patients with T2DM and elevated
HbA1c (mean baseline HbA1c 9.5%) [4]. SAXA was
tested in combination at doses of 5 and 10 mg but the
results were very similar. At week 76, reduction from
baseline HbA1c w a sg r e a t e ri nt h eS A X Ap l u sM E T
groups compared with the monotherapy groups (- 2.3%
vs -1.6% with SAXA alone and -1.8% with MET alone)
and the proportion of patients reaching target HbA1c <
7% was also greater (51% vs 25% and 35%, respectively).
Incidence of adverse events was almost identical across
groups (SAXA 10 mg plus MET 68.4%, SAXA plus pla-
cebo 66.3%, MET plus placebo 68.3%). In addition, the
SAXA plus MET combination showed no increase in
hypoglycemia compared with either monotherapy [4].
Pharmacokinetic analyses
In the basic field, Zhang et al presented an abstract at
ADA characterizing the pharmacokinetics of SAXA and
its major active metabolite, 5-hydroxy SAXA, in healthy
subjects and in patients with T2DM, in order to quan-
tify the impact of subject-specific covariates on exposure
and support the dosing recommendation in patients
with T2DM, as well as its use in special populations [5].
The pharmacokinetics of SAXA and 5-hydroxy SAXA
can be adequately described by a two-compartment lin-
ear model with no time-variant parameters, and were
similar in healthy subjects and in patients with T2DM.
There was no appreciable accumulation after once-daily
dosing. Renal function (estimated by creatinine clear-
ance) was identified as a significant covariate on the
apparent clearance of SAXA and 5-hydroxy SAXA from
the central compartment. No pharmacokinetic para-
meters were affected significantly by gender, body
weight, age, or race. Results from exposure modeling of
SAXA and 5-hydroxy SAXA in healthy subjects and in
T2DM patients support once-daily dosing of SAXA
without dosage adjustment on the basis of body weight,
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should be taken into consideration when assessing
SAXA dosage [5].
Monotherapy in patients with renal impairment
To explore the clinical use of SAXA in patients with
renal impairment, a multicenter, randomized, double-
blind, parallel-group, placebo-controlled 12-week study
conducted to the assess the efficacy and safety of SAXA
2.5 mg/day in adult patients with T2DM, HbA1c
7%-11%, and moderate (estimated creatinine clearance
≥0.50 to <0.84 mL/s) to severe (creatinine clearance
<0.50 mL/s) renal impairment, including end-stage renal
disease (ESRD) with hemodialysis [6]. Patients (96%)
continued background oral antidiabetic (32%) and/or
insulin (74%) therapy as prescribed. The results, which
were presented by Nowicki et al at ADA, showed that
the overall mean reduction in HbA1c from baseline to
week 12 for patients with renal impairment was signifi-
cantly greater with SAXA versus placebo. Subgroup
results by baseline renal impairment category showed
numerically greater reductions in HbA1c with SAXA
versus placebo in patients with moderate or severe renal
impairment, while the HbA1c reduction in patients with
ESRD on hemodialysis was similar between the treat-
ment groups. SAXA was well tolerated, with a safety
profile similar to placebo (adverse events were experi-
enced by 57.6% of patients in the SAXA group, com-
pared with 54.1% in the placebo group; hypoglycemia
was reported in 20.0% of SAXA patients vs 22.4% of pla-
cebo patients) [6]. Based on these results, SAXA could
also be considered as the antidiabetic drug in patients
with moderate or severe renal impairment, where insu-
lin is usually the drug of choice and MET is contraindi-
cated, although it is not recommended for patients with
ESRD on hemodialysis.
b-cell preservation
Incretins and particularly glucagon-like peptide-1 (GLP-
1) have a very promising effect on b-cell mass by inhi-
biting apoptosis and even stimulating b-cell formation
from precursor cells. This has been demonstrated
in vitro and in vivo in rodents. At EASD Poucher et al
presented an experiment comparing the effect of SAXA
and sitagliptin (SITA) - which inhibit DPP4 and reduce
its deactivation of GLP-1 - on the preservation of pan-
creatic b-cell mass in high fat-fed streptozocin (STZ)-
treated mice [7]. Glycemic control was determined by
oral glucose tolerance tests and fasting blood glucose
3 weeks and 36 days, respectively, following STZ treat-
ment. Terminal formalin-fixed, paraffin-embedded sam-
ples, taken 36 days after initiation of treatment, were
analyzed for b-cell mass using automated imaging and
analysis systems. In animals treated post-STZ, HbA1c
levels compared with vehicle dosing (6.8%) were signifi-
cantly lower with either SAXA (6.1%; p < 0.01) or SITA
6.3% (p < 0.05). b-cell mass was also significantly greater
with SAXA (0.28 mg) and with SITA (0.42 mg) than
with vehicle (p < 0.05 for both). Overall, both DPP4
inhibitors showed similar improvements in glycemic
control and b-cell mass preservation in the high fat-fed,
STZ mouse model of pancreatic b-cell degeneration [7].
T h i sh a db e e na l r e a d ys h o w nw i t hS I T Ab u ti tw a s
demonstrated for the first time with SAXA.
Advantages of reduced hypoglycemia for patients
There were two additional abstracts presented at EASD
that highlight the advantage of treatments such as
SAXA that do not increase hypoglycemia: both reported
the results of the PANORAMA study, a large pan-
European cross-sectional survey (NCT00916513) of
patients with T2DM treated with glucose-lowering thera-
pies (either oral hypoglycemic agents [OHAs] or inject-
ables - insulin and GLP-1 receptor analogues - with or
without OHAs) [8,9]. Eligible patients were ≥40 years of
age with a diagnosis of T2DM for >1 year prior to study
entry and an available medical record at the clinic of
>1 year. The analyses aimed to assess treatment satisfac-
tion, quality of life, and the proportion of patients achiev-
ing an HbA1c < 7%. One of the abstracts reported recent
data from nine countries on glycemic control in patients
with T2DM in relation to treatment patterns. They found
that although the level of glycemic control in Europe may
be improving, there is still a gap between current manage-
ment and optimal treatment of patients with T2DM [8].
The failure to reach target was greater as treatment was
intensified, possibly due a longer duration of T2DM and
to the concern over hypoglycemia. In fact, the authors
demonstrate that the occurrence of both severe and non-
severe hypoglycemia in T2DM is associated with a greater
negative impact of diabetes on quality of life, less treat-
ment satisfaction, and greater fear of hypoglycemia, which
may be an important barrier to optimal glycemic control
in some patients [9].
Conclusion
Abstracts presented at the ADA and EASD 2010 meet-
ings show that SAXA is a potent, selective DPP4 inhibi-
tor, which can be given once a day as an add-on therapy
to patients on MET, SU, or TZD. Being an insulin
secretagogue, it is as effective as an SU but without sig-
nificant hypoglycemia and no weight gain. It is particu-
larly effective in combination with MET as initial
therapy and also well tolerated across different patient
profiles, including patients with renal impairment
receiving a reduced dose. DPP4 inhibitors may have a
potential role in preserving b-cell function, although this
has to be demonstrated in humans.
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